Skip to main content
Signal8

Ventana Biotech, Inc. (VNTA)

Ventana Biotech, Inc. is an emerging biotechnology enterprise focused on the lifecycle of drug candidates for personalized medicine, encompassing the identification, assessment, acquisition, development, and eventual commercialization through partnerships of relevant intellectual property. The company's primary therapeutic area is addressing obesity and its associated medical conditions. Notably, Ventana holds proprietary rights to a medicated chewing gum formulation that integrates an extract of hoodia gordonii and 2-hydroxyoleic acid. This unique composition is intended for the management of obesity, hypertension, and various other metabolic disorders. Ventana is actively engaged in developing these appetite-suppressant chewing gums into distinct products: a lower-dosage version aimed at the over-the-counter market, and a higher-dosage variant slated for distribution via pharmacists. The lower-strength product is expected to be retailed in drugstores and health food establishments. Established in 1989, Ventana Biotech, Inc. operates from Butschwil, Switzerland. The company adopted its current name in October 2008, having previously been known as Personalica, Inc.

Sector: Financial - Credit Services

Industry: Financial - Credit Services

Ventana Biotech, Inc. logo

Ventana Biotech, Inc.

OTC:VNTAFinancial Services
-16.67%$0.0400
CLOSED
Mkt Cap$132K
EV$180K
Float-
O/S3.3M
VOL40K sh
$ Vol$2K
RVOL2.48×
Inst Own-
Net Cash/Sh-$0.01
Dilution
Financials Summary
Revenue$115K
Net Income$86K
Total Assets$62K
Free Cash Flow-$54K
Debt & Equity
Debt 191%
Total Debt$110K
Total Equity-$52K
Shares Outstanding
Short Interest

No short interest data available.

Split History2 splits · 2 reverse
2-year cumulative
1:20

Nasdaq bars a compliance period at 1:250

  1. 1:20Reverse split
    Jan 15, 202520 shares → 1
  2. 1:30Reverse split
    Nov 13, 200630 shares → 1
Balance Sheet Details
Assets$62K
Liabilities$114K
Accounts Receivable$0
Accounts Payable$4K
Inventory$0
PP&E (Net)$0
Goodwill$0
Intangible Assets$0
Income Statement
PeriodFY 2025FY 2024FY 2023FY 2021FY 2019FY 2018FY 2008FY 2007
CurrencyUSDUSDUSDUSDUSDUSDUSDUSD
Period Ending2025-12-312024-12-312023-12-312021-12-312019-12-312018-12-312009-04-302008-04-30
Revenue$115K$41K$32K$0$0$0$0$0
YoY Growth177.0%29.9%------
Cost of Revenue$0$41K$32K$0$0$0$3K$0
Gross Profit$0$0$0$0$0$0-$3K$0
Gross Margin--------
Research and Development$0$0$0$0$0$0$0$0
Selling, General, and Administrative$14K$21K$13K$7K$300$600$40K$164K
Other$0$0$0$0$0$0$0$0
Total Operating Expenses$14K$21K$13K$7K$300$600$40K$164K
Operating Income (EBIT)$101K$21K$18K-$7K-$300-$600-$43K-$164K
Operating Margin88.0%50.3%58.0%-----
Interest Expense$0$33$0$75K$5K$3K$4K$2K
Interest Income$0$0$0$0$0$0$0$0
Other Income (Expense)$125-$33$0-$75K-$5K-$3K-$4K-$2K
Income Before Tax (EBT)$101K$21K$18K-$82K-$5K-$4K-$47K-$166K
Income Tax Expense$15K$872$1K$0$0$0$0$0
Net Income$86K$20K$17K-$82K-$5K-$4K-$47K-$166K
Net Income Margin75.2%48.1%54.3%-----
Supplementary Data
EPS0.000.000.00-0.00-0.00-0.00-0.02-0.00
Diluted EPS0.000.000.00-0.00-0.00-0.00-0.02-0.00
Weighted Average OS53.78M53.78M53.78M31.64M5.38M5.38M2.76M239.35M
EBITDA$101K$21K$18K-$7K-$300-$600-$40K-$164K
EBITDA Margin88.0%50.3%58.0%-----
Balance Sheet
PeriodFY 2024FY 2023FY 2008
CurrencyUSDUSDUSD
Period Ending2024-12-312023-12-312009-04-30
Assets
Current Assets
Cash and Cash Equivalents$62K$34K$0
Short-Term Investments$0$0$0
Cash and Short-Term Investments$62K$34K$0
Accounts Receivable$0$0$0
Inventory$0$0$0
Other Current Assets$0$0$0
Total Current Assets$62K$34K$3K
Long-Term Assets
Property, Plant & Equipment Net$0$0$0
Goodwill$0$0$0
Intangible Assets$0$0$57K
Long-Term Investments$0$0$0
Deferred Tax Assets$0$0$0
Other Long-Term Assets$0$0$0
Total Long-Term Assets$0$0$57K
Other Assets$0$0$0
Total Assets$62K$34K$59K
Liabilities
Current Liabilities
Accounts Payable$4K$300$0
Short-Term Debt$110K$105K$141K
Current Income Tax Payable$0$0$0
Current Unearned Revenue$0$0$0
Other Current Liabilities$0$0$1K
Total Current Liabilities$114K$106K$142K
Long-Term Liabilities
Long-Term Debt$0$0$0
Long-Term Unearned Revenue$0$0$0
Long-Term Deferred Tax Liabilities$0$0$0
Other Long-Term Liabilities$0$0$0
Total Long-Term Liabilities$0$0$0
Other Liabilities$0$0$0
Total Liabilities$114K$106K$142K
Stockholders' Equity
Preferred Stock$0$0$0
Common Stock$108K$108K$55K
Retained Earnings-$234K-$254K-$238K
Comprehensive Income & Other$0$0$0
Other Stockholders' Equity$75K$75K$100K
Total Equity-$52K-$72K-$83K
Minority Interest$0$0$0
Total Liabilities and Equity$62K$34K$59K
Supplementary Data
Total Debt$110K$105K$141K
Net Debt$48K$71K$141K
Cash Flow Statement
PeriodFY 2008
CurrencyUSD
Period Ending2009-04-30
Operating Activities
Net Income-$47K
Depreciation & Amortization$3K
Deferred Income Tax$0
Stock-Based Compensation$0
Changes in Working Capital:
  Accounts Receivable$0
  Inventory$0
  Accounts Payable$0
  Other Working Capital-$14K
Total Working Capital Change-$14K
Other Non-Cash Items$4K
Net Cash from Operating-$54K
Investing Activities
Capital Expenditures-$60K
Acquisitions$0
Purchases of Investments$0
Sales of Investments$0
Other Investing Activities$0
Net Cash from Investing-$60K
Financing Activities
Debt Repaid-$114K
Common Stock Issuance$0
Common Stock Repurchases$0
Dividends Paid$0
Other Financing Activities$0
Net Cash from Financing$114K
Forex Effect$0
Net Change in Cash$0
Supplementary Data
Operating Cash Flow-$54K
Capital Expenditure$0
Free Cash Flow-$54K
Cash at Beginning$0
Cash at End$0